Drug Discovery

Historical failures in the vitiligo pipeline, such as the cancellation of the AC##4 trial in 2016, highlight the difficulty of establishing a global site network. The recent publication of the Viti-Up Phase 3 clinical trial results in The Lancet marks a transformative moment for dermatologic

When levels of miR-342 drop, the E2F genetic pathway is unleashed, signaling disseminated cancer cells to begin the rapid multiplication required to form tumors. This mechanism serves as a terrifying catalyst for triple-negative breast cancer, a subtype that has historically defied the precision

A strategic partnership with a pharmaceutical firm allows Outer Biosciences to investigate the biological mechanisms behind skin rashes caused by cancer treatments. This initiative marks a significant departure from traditional dermatological research, signaling a move toward high-precision,

Early-stage venture capital is increasingly tied to operational readiness, where a startup's ability to automate research serves as a primary signal of its maturity and future potential. This paradigm shift occurs at a time when the historical trajectory of hard-tech startups has long been defined

For the 15,000 Americans living with Duchenne muscular dystrophy, the three-month regulatory delay represents a critical window where irreversible physical decline remains a constant threat. This extension, moving the target decision date from August to November 22, 2026, occurred after the Food

By integrating a selectively permeable endothelial lining, this new technology forces cancer cells to demonstrate their ability to traverse vessel walls. This breakthrough represents a monumental shift in oncology, moving away from the static culture plates and animal models that have dominated